These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25496406)

  • 1. Successful treatment with tocilizumab of a psoriasiform skin lesion induced by etanercept in a patient with juvenile idiopathic arthritis.
    Shimizu M; Hamaguchi Y; Ishikawa S; Ueno K; Yachie A
    Mod Rheumatol; 2015; 25(6):972-3. PubMed ID: 25496406
    [No Abstract]   [Full Text] [Related]  

  • 2. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy.
    Boqaeid A; Layqah L; Alonazy A; Althobaiti M; Almahlawi AZ; Al-Roqy A; Baharoon O; Alsaeedi A; Shamou J; Baharoon S
    J Infect Public Health; 2024 Jun; 17(6):1134-1141. PubMed ID: 38728834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incident psoriasis under treatment with tumor necrosis factor-α inhibitors in juvenile idiopathic arthritis patients-analysis of the BiKeR registry.
    Zimmer A; Klein A; Kuemmerle-Deschner JB; Dressler F; Onken N; Brueck N; Fasshauer M; Hospach T; Hufnagel M; Foell D; Horneff G
    Rheumatol Int; 2023 Sep; 43(9):1675-1684. PubMed ID: 37291093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.
    Klein A; Klotsche J; Hügle B; Minden K; Hospach A; Weller-Heinemann F; Schwarz T; Dressler F; Trauzeddel R; Hufnagel M; Foeldvari I; Borte M; Kuemmerle-Deschner J; Brunner J; Oommen PT; Föll D; Tenbrock K; Urban A; Horneff G
    Rheumatology (Oxford); 2020 Sep; 59(9):2287-2298. PubMed ID: 31846042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab for treating juvenile idiopathic arthritis.
    Turnier JL; Brunner HI
    Expert Opin Biol Ther; 2016; 16(4):559-66. PubMed ID: 26848760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab-induced psoriasiform rash in rheumatoid arthritis.
    Palmou-Fontana N; Sánchez Gaviño JA; McGonagle D; García-Martinez E; Iñiguez de Onzoño Martín L
    Dermatology; 2014; 228(4):311-3. PubMed ID: 24942661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous Tocilizumab May Be Less Effective than Intravenous Tocilizumab in the Treatment of Juvenile Idiopathic Arthritis-associated Uveitis.
    Quesada-Masachs E; Caballero CM
    J Rheumatol; 2017 Feb; 44(2):260-261. PubMed ID: 28148759
    [No Abstract]   [Full Text] [Related]  

  • 10. Incidence of herpes zoster infections in juvenile idiopathic arthritis patients.
    Nimmrich S; Horneff G
    Rheumatol Int; 2015 Mar; 35(3):465-70. PubMed ID: 25583050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologicals in Juvenile Idiopathic Arthritis.
    Saini I; Dawman L; Gupta N; Kabra SK
    Indian Pediatr; 2016 Mar; 53(3):260-1. PubMed ID: 27029697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidance on using tocilizumab for juvenile idiopathic arthritis.
    Yokota S; Imagawa T; Takei S; Murata T; Tomiita M; Itoh Y; Fujikawa S; Mori M
    Mod Rheumatol; 2011 Dec; 21(6):563-71. PubMed ID: 21597951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?
    Tappeiner C; Heinz C; Ganser G; Heiligenhaus A
    J Rheumatol; 2012 Jun; 39(6):1294-5. PubMed ID: 22661419
    [No Abstract]   [Full Text] [Related]  

  • 14. Monitoring serum etanercept levels in juvenile idiopathic arthritis: a pilot study.
    Alcobendas R; Rodríguez-Vidal A; Pascual-Salcedo D; Murias S; Remesal A; Diego C; Merino R
    Clin Exp Rheumatol; 2016; 34(5):955-956. PubMed ID: 27156742
    [No Abstract]   [Full Text] [Related]  

  • 15. AKI in a Patient on Etanercept for Juvenile Idiopathic Arthritis.
    Al-Sammarraie R; Segamwenge I; Robertson S
    Kidney360; 2024 Feb; 5(2):327-328. PubMed ID: 38421859
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan.
    Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    Ann Rheum Dis; 2013 Apr; 72(4):627-8. PubMed ID: 23204515
    [No Abstract]   [Full Text] [Related]  

  • 17. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis.
    Liu SW; Velez NF; Lam C; Femia A; Granter SR; Townsend HB; Vleugels RA
    JAMA Dermatol; 2013 Oct; 149(10):1204-8. PubMed ID: 23986394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting.
    Tarkiainen M; Tynjälä P; Vähäsalo P; Lahdenne P
    Rheumatology (Oxford); 2015 Jul; 54(7):1170-6. PubMed ID: 25504896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of biologic therapies for the treatment of juvenile idiopathic arthritis.
    Horneff G
    Expert Opin Drug Saf; 2015 Jul; 14(7):1111-26. PubMed ID: 26084637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.